DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/1ea46f/cervical_cancer_th) has announced the addition of GlobalData's new report "Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.
GlobalData, the industry analysis specialist, has released its new report, Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Cervical Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Cervical Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cervical Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
The Cervical Cancer Market is Forecast to Show Slow Growth Until 2018:
GlobalData estimates that the global cervical cancer market was worth $1,793.3m in 2010, after increasing at a Compound Annual Growth Rate (CAGR) of 62.7% during 2006-2010. During 2010-2018, the market is expected to record a CAGR of 3.6%, from $1,793.3m in 2010 to $2,377.3m in 2018.
The overall cervical cancer market consists of the cervical cancer prophylactics market and the cervical cancer therapeutics market. The cervical cancer prophylactics market grew at a CAGR of 61.5% from $234.8m in 2006 to $1,598.7m in 2010. The cervical cancer therapeutics market grew at a CAGR of 4.3% from $157.3m in 2005 to $194.5m in 2010.
Growth in the cervical cancer therapeutics market is expected to decline in the forecast period until 2018, primarily due to the generic erosion of Hycamtin, the only approved therapeutic treatment option available in the market for advanced and recurrent cervical cancer patients. Its patent expired in the US in 2010 and will expire in Europe in 2011. In Japan, the therapeutics market is expected to show steady growth during the forecast period, attributed to the expected launch of two upcoming FIC molecules.
Key Topics Covered:
- List of tables and figures
- Cervical Cancer - Introduction
- Cervical Cancer - Market Characterization
- Cervical Cancer Market - Competitive Assessment
- Cervical Cancer - Pipeline Assessment
- Cervical Cancer - Clinical Trials Mapping
- Cervical Cancer - Strategic Assessment
- Cervical Cancer - Future Players
- Cervical Cancer: Licensing and Partnership Deals
- Cervical Cancer Therapeutics - Appendix
Companies Mentioned:
- Merck & Co., Inc. (Merck).
- Sanofi Pasteur MSD (Subsidiary of Merck & Co., Inc.)
- GlaxoSmithKline plc (GSK)
- Zeria Pharmceutical Co., Ltd. (Zeria)
- Taiho Pharmaceutical Co., Ltd. (Subsidiary of Otsuka Holdings Co., Ltd.)
For more information visit http://www.researchandmarkets.com/research/1ea46f/cervical_cancer_th